BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Califf Closes in on Second Stint as FDA Commissioner Despite Opposition

  Robert Califf’s nomination to resume his role as FDA Commissioner continues to advance in the Senate, despite some opposition from a key Democrat, Sen. Joe Manchin.

  February 15, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  BMS-Exelixis Combo Sustained 2-Year Survival for Kidney Cancer Patients

  Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).

  February 15, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Lilly, Innovent and the Question of Clinical Trial Representation

  The unspoken challenge is: how diverse can a trial run in the United States really be right now?

  February 15, 2022

   · 

  4 min read

   · 

  Heather McKenzie
• 

  BioCapital

  6-Month Use of Implanted Continuous Glucose Monitoring System Finally Approved

  Senseonics has finally received approval from the U.S. Food and Drug Administration for its Eversense E3 Continuous Glucose Monitoring System (CGM) System.

  February 15, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Proactive > Reactive: Science Targets Universal Coronavirus Vaccine

  While the “speed of science” to develop a successful coronavirus vaccine against the novel COVID-19 has been record-setting, scientists are telling us it’s not enough.

  February 15, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Three Big Antibody Research Collabs Hit the Wire

  Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.

  February 15, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Califf Wins Second Act as FDA Boss in Narrow Senate Vote

  After a filibuster was broken Monday, the Senate confirmed Califf’s nomination in a 50-46 bipartisan vote.

  February 15, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Intellia Adds ONK’s NK Cells to Cancer Immunotherapy Portfolio

  Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.

  February 15, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Business

  Genomenon Scores $1.7M SBIR Grant to Curate Genetic Drivers of Disease

  The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.

  February 15, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Money on the Move: February 9 – 15

  As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.

  February 15, 2022

   · 

  3 min read

   · 

  Kate Goodwin